Company Overview
Company Type: Public Company
Website: www.covalon.com
Number of Employees: 37
Ticker: COV (TSXV)
Year Founded: -


Business Description
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company’s direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. The company is headquartered in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
25.1
Market Capitalization
30.8
TEV/Total Revenue
0.9x
EBITDA
(4.9)
Total Enterprise Value
23.3
TEV/EBITDA
NM
EBIT
(5.7)
Cash & ST Invst.
9.2
P/Diluted EPS Before Extra
NM
Net Income
(5.7)
Total Debt
1.7
Price/Tang BV
1.6x
Capital Expenditure
(0.7)
Total Assets
26.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Boloor, Amir 
Interim CEO & Chairman of the Board
Pedlar, Brian E.
President & Director
DiTizio, Valerio 
Co-Founder, Chief Scientific Officer & VP
Gorel, Jason F.
Interim Chief Financial Officer
Zhang, Elaine 
Vice President of Operations
Hebert, Ronald 
Senior Vice President of Growth Marketing
Leszczynski, Greg 
Vice President of Human Resources
Doolittle, Mark 
Senior Vice President of Commercial Operations
Arambula, Gerry 
President of Covalon Technologies AG Ltd.
Abbasian, Hamed 
Vice President of Business Development
Hill, Emily 
Executive Assistant to the CEO

Key Board Members
Name
Title
Boloor, Amir 
Interim CEO & Chairman of the Board
Pedlar, Brian E.
President & Director
Cordiano, Joseph 
Lead Independent Director
Smith, Ronald E.
Independent Director
Goldfarb, Martin 
Director
Nutt, Samantha 
Director
Schwartz, Abe 
Director


Primary Industry Classification
Biotechnology


Primary Office Location
1660 Tech Avenue Unit 5 | Mississauga, ON | L4W 5S7 | Canada
Phone: 905 568 8400   Fax: 905 568 5200

Current and Pending Investors
Accretive Capital Corp., Almada Inc., Chord Management Inc, ISYMAX Corp., Mitec Technologies, Inc., The Goldfarb Corporation

Prior Investors
Mackenzie Financial Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.25
Market Cap (mm)
30.8
Open
 1.25
Shares Out. (mm)
24.7
Previous Close
 1.25
Float %
50.6%
Change on Day
(0.25)
Shares Sold Short (mm)
-
Change % on Day
(16.7)%
Dividend Yield %
-
Day High/Low
 1.25/ 1.25
Diluted EPS Excl. Extra Items
(0.23)
52 wk High/Low
 2.49/ 1.25
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0003
Avg 3M Dly Vlm (mm)
0.0035
Beta 5Y
0.85


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
TSXV:COV - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
AquaGuard Business of Cenorin, L.L.C.
As of October 1, 2018, AquaGuard Business of Cenorin, L.L.C. was acquired by Covalon Technologies Ltd. AquaGuard Business of Cenorin, L.L.C. comprises business division that manufactures moisture protection for wound, surgical, and vascular access sites throughout the body while showering. The asset is located in the United States.

United States and Canada
Health Care Supplies
-
-
-
Seder Capital Corp.
Seder Capital Corp. was acquired by Covalon Technologies Inc. on 12/21/2004 in a reverse merger transaction. Seder Capital Corp. is a capital pool company based in Richmond Hill, Canada.

United States and Canada
Biotechnology
-
-
-
Perfusion Therapeutics Inc.
Perfusion Therapeutics Inc. was acquired by Covalon Technologies Ltd. Perfusion Therapeutics Inc. develops cell engineering platform for improving localized blood flow. The company is based in Montreal, Canada. 

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-25-2022
-
Buyback
Target
Covalon Technologies Ltd. (TSXV:COV)


-
Jul-29-2021
Jul-29-2021
Merger/Acquisition
Seller
Covalon Technologies Holdings (USA), Ltd./Covalon Technologies AG Ltd.
TIDI Products, LLC
Covalon Technologies Ltd. (TSXV:COV)
30.00
Aug-24-2020
Aug-24-2020
Merger/Acquisition
Seller
Saudi Arabian business of Covalon Technologies

Covalon Technologies Ltd. (TSXV:COV)
-
Aug-01-2019
Sep-18-2019
Private Placement
Target
Covalon Technologies Ltd. (TSXV:COV)
Almada Inc.,Chord Management Inc

4.14
Sep-20-2018
Oct-01-2018
Merger/Acquisition
Buyer
AquaGuard Business of Cenorin, L.L.C.
Covalon Technologies Ltd. (TSXV:COV)
Cenorin, LLC
12.45
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Special Calls
Covalon Technologies Ltd. - Special Call
Sep-26-2023
Executive/Board Changes - Other
Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent Director
Sep-26-2023
Executive Changes - CEO
Covalon Technologies Ltd. Announces Chief Executive Officer Changes
Sep-21-2023
Company Conference Presentations
Covalon Technologies Ltd. Presents at 47th annual Association of Pediatric Hematology/Oncology Nurses (“APHON”) Conference and Exhibit, Sep-21-2023
Aug-16-2023
Earnings Calls
Covalon Technologies Ltd., Q3 2023 Earnings Call, Aug 16, 2023

M&A Advisors
Foley & Lardner LLP, MPA Morrison Park Advisors Inc., Stikeman Elliott LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Foley & Lardner LLP, MPA Morrison Park Advisors Inc., Stikeman Elliott LLP
Private Placement Advisors
Desjardins Securities Inc., Jennings Capital Inc., Octagon Capital Corporation
Key development Advisor
MPA Morrison Park Advisors Inc.


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:40 AM
COV
Covalon Technologies Ltd 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:06 AM
COV
ValuEngine - Toronto Quantitative Stock Report for COV
Reports
5
CFRA Equity Research

Oct 01, 2023 11:05 AM
COV
Covalon Technologies Ltd.
Reports
9
GlobalData

Sep 21, 2023 05:43 AM
COV
Covalon Technologies Ltd (COV.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
45
MarketLine

Sep 14, 2023 06:01 AM
COV
Covalon Technologies Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
138
GlobalData

Sep 11, 2023 11:12 PM
COV
Covalon Technologies Ltd (COV.CVE) - Financial Analysis Review
Reports
229
S&P Global Compustat

Sep 07, 2023 03:27 AM
COV
Covalon Technologies Ltd 2023_09_07
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 06, 2023 06:00 PM
COV
Rating Update for Covalon Technologies Ltd
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 13, 2023 06:00 PM
COV
Rating Update for Covalon Technologies Ltd
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 03:03 AM
COV
Covalon Technologies Ltd 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Schwartz, Abe 

8,160,912

33.08

10.2

Jan-18-2023


The Goldfarb Corporation

2,056,655

8.34

2.6

Jan-18-2023


Goldfarb Ventures Corp.

1,020,408

4.14

1.3

Jan-18-2023


Almada Inc.

1,000,000

4.05

1.3

Jan-18-2023


Pedlar, Brian E.

883,876

3.58

1.1

Jan-18-2023


Boloor CFA, Amir 

869,598

3.52

1.1

Jan-18-2023


Cordiano, Joseph 

90,000

0.36

0.1

Jan-18-2023


Chord Management Inc

62,200

0.25

0.1

Jan-18-2023


Goldfarb O.C., Martin 

34,500

0.14

0.0

Jan-18-2023


Smith B.B.A., BBA, F.C.A., FCA, FCPA, ICD.D, Ronald E.

17,500

0.07

0.0

Jan-18-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AquaGuard Boots, AquaGuard Gloves, AquaGuard Sheet, ColActive Ag Collagen, ColActive Plus, ColActive Plus Ag, ColActive Plus Powder, ColActive Plus Powder Ag, ColActive Transfer, CovaClearAg (Future), CovaCoat AI, Covacoat Machine, CovaGuard Antimicrobial Hand Sanitizer, CovaGuard Mask Antimicrobial Sanitizer, CovaView Transparent IV Dressing, CovaWound Alginate, CovaWound Alginate Ag, CovaWound Foam, CovaWound Foam with Border, CovaWound Hydrocolloid, CovaWound Silicone, CovaWound Silicone Heel, CovaWound Silicone Sacrum, CovaWound Silicone with Border, CovaWound Super Absorbent, Development and Consulting Services, EPAS1 (Future), IV Clear, Medical Coating Systems, MediClear Post-Op Absorb, MediClear Pre-Op, MediClear Scar, Midstream Urine Testing Device (Future), Silver Lactate Devices (Future), SilverCoat Foley Catheter, SurgiClear, VAL Guard


Upcoming Events
Date/Time
Type
Dec-13-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-02-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
Material Change Report
66 KB
Sep-26-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
273 KB
Sep-26-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
273 KB
Sep-25-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
390 KB
Sep-25-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
390 KB
Sep-19-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
326 KB
Aug-16-2023
Jun-30-2023
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
Interim Financial Statements
803 KB
Aug-16-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
284 KB
Aug-14-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
233 KB
Jul-18-2023
-
Covalon Technologies Ltd. (TSXV:COV)
SEDAR
News Releases
262 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Boloor CFA, Amir  (Interim CEO & Chairman of the Board)
Jun-02-2022
Common Shares
9,900
22,260
Open Market Acquisition
1.15
Multiple
Brannagan, Danny  (Former Chief Financial Officer)
Sep-13-2021
Common Shares
25,000
40,280
Derivative Exercise and Retained Stock
454.55
Multiple
-
Sep-13-2021
Common Shares
20,000
27,899
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Sep-13-2021
Common Shares
5,000
12,381
Derivative Exercise and Retained Stock
-
Exchange Announcement
Boloor CFA, Amir  (Interim CEO & Chairman of the Board)
Sep-09-2021 - Sep-10-2021
Common Shares
30,600
87,819
Open Market Acquisition
3.69
Multiple
-
Sep-09-2021
Common Shares
5,000
13,292
Open Market Acquisition
-
Exchange Announcement
-
Sep-10-2021
Common Shares
25,600
74,527
Open Market Acquisition
-
Exchange Announcement
Cordiano, Joseph  (Lead Independent Director)
Sep-08-2021
Common Shares
5,000
6,948
Derivative Exercise and Retained Stock
5.88
Multiple
Boloor CFA, Amir  (Interim CEO & Chairman of the Board)
Sep-08-2021
Common Shares
45,000
110,523
Open Market Acquisition
5.74
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Boloor, Amir 
Interim CEO & Chairman of the Board
(604) 362-4155
905 568 5200
amir@gbaequity.com
Pedlar, Brian E.
President & Director
905-568-8400x233
905 568 5200
bpedlar@covalon.com
Cordiano, Joseph 
Lead Independent Director
905 568 8400
905 568 5200

Smith, Ronald E.
Independent Director
905 568 8400
905 568 5200

Goldfarb, Martin 
Director
(416) 833-1774
905 568 5200
mgoldfarb@almadainvestments.com
Nutt, Samantha 
Director
905 568 8400
905 568 5200
samantha@warchild.ca
Schwartz, Abe 
Director
905 568 8400
905 568 5200

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Boloor, Amir 
Interim CEO & Chairman of the Board
(604) 362-4155
905 568 5200
amir@gbaequity.com
Pedlar, Brian E.
President & Director
905-568-8400x233
905 568 5200
bpedlar@covalon.com
DiTizio, Valerio 
Co-Founder, Chief Scientific Officer & VP
905 568 8400
905 568 5200

Gorel, Jason F.
Interim Chief Financial Officer
905 568 8400
905 568 5200

Zhang, Elaine 
Vice President of Operations
905 568 8400
905 568 5200

Hebert, Ronald 
Senior Vice President of Growth Marketing
905 568 8400
905 568 5200

Leszczynski, Greg 
Vice President of Human Resources
905 568 8400
905 568 5200
-
Doolittle, Mark 
Senior Vice President of Commercial Operations
905 568 8400
905 568 5200

Arambula, Gerry 
President of Covalon Technologies AG Ltd.
905 568 8400
905 568 5200

Abbasian, Hamed 
Vice President of Business Development
905 568 8400
905 568 5200
-
Hill, Emily 
Executive Assistant to the CEO
905 568 8400
905 568 5200

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
